Tag: Reversible antiplatelets

Antiplatelet agents, including P2Y12 inhibitors, are a cornerstone of preventing thrombotic events in cardiovascular disease. Understanding **which P2Y12 inhibitors are reversible** versus irreversible is critical, as this fundamental pharmacological difference dictates their onset, offset, and specific clinical applications.

With the global antiplatelet market projected to reach $5.1 billion by 2030, understanding their properties is crucial [1.10.1]. The critical question for clinicians and patients alike is, **are antiplatelets reversible**, and what does that mean for managing bleeding or emergency surgery?